Article Details

Immix Biopharma to Launch Underwritten Public Offering - MarketWatch

Retrieved on: 2024-02-05 20:45:04

Tags for this article:

Click the tags to see associated articles and topics

Immix Biopharma to Launch Underwritten Public Offering - MarketWatch. View article details on hiswai:

Summary

The article discusses NXC-201 clinical trials targeting AL amyloidosis—a proteinopathy linked to protein misfolding, causing organ damage which is categorically a form of amyloidosis and associated with neurological disorders and pathology.

Article found on: www.marketwatch.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up